Anixa Biosciences, Inc. (ANIX)
3.07
+0.02
(+0.66%)
USD |
NASDAQ |
Sep 04, 16:00
3.07
0.00 (0.00%)
Pre-Market: 20:00
Anixa Biosciences Research and Development Expense (Quarterly) : 1.258M for April 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| April 30, 2026 | 1.258M |
| January 31, 2026 | 1.102M |
| October 31, 2025 | 1.142M |
| July 31, 2025 | 1.055M |
| April 30, 2025 | 1.322M |
| January 31, 2025 | 1.552M |
| October 31, 2024 | 1.476M |
| July 31, 2024 | 1.925M |
| April 30, 2024 | 1.646M |
| January 31, 2024 | 1.349M |
| October 31, 2023 | 1.615M |
| July 31, 2023 | 1.088M |
| April 30, 2023 | 0.998M |
| January 31, 2023 | 1.068M |
| October 31, 2022 | 1.685M |
| July 31, 2022 | 1.445M |
| April 30, 2022 | 1.735M |
| January 31, 2022 | 1.838M |
| October 31, 2021 | 2.173M |
| July 31, 2021 | 2.167M |
| April 30, 2021 | 1.022M |
| January 31, 2021 | 0.8277M |
| October 31, 2020 | 0.4077M |
| July 31, 2020 | 1.254M |
| April 30, 2020 | 1.229M |
| Date | Value |
|---|---|
| January 31, 2020 | 1.491M |
| October 31, 2019 | 0.8566M |
| July 31, 2019 | 1.086M |
| April 30, 2019 | 1.269M |
| January 31, 2019 | 2.247M |
| October 31, 2018 | 2.433M |
| July 31, 2018 | 2.942M |
| April 30, 2018 | 0.6602M |
| January 31, 2018 | 0.7779M |
| October 31, 2017 | 0.3518M |
| July 31, 2017 | 0.363M |
| April 30, 2017 | 0.4311M |
| January 31, 2017 | 0.4516M |
| October 31, 2016 | |
| July 31, 2016 | |
| April 30, 2016 | |
| January 31, 2016 | |
| October 31, 2015 | |
| July 31, 2015 | |
| April 30, 2015 | |
| January 31, 2015 | |
| October 31, 2014 | |
| July 31, 2014 | |
| April 30, 2014 | |
| January 31, 2014 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 192.06M |
| Oncolytics Biotech, Inc. | 4.262M |
| Sangamo Therapeutics, Inc. | 26.57M |
| Sarepta Therapeutics, Inc. | 91.26M |
| Vicapsys Life Sciences, Inc. | 0.00 |